Lipocine Inc.’s SEC filings document the regulatory record for a clinical-stage biopharmaceutical company focused on oral drug-delivery products. Recent 8-K filings furnish financial results, operational updates, corporate presentations and clinical disclosures for LPCN 1154 in postpartum depression, along with information on TLANDO licensing and royalty-related business activity.
The company’s filings also cover governance and capital-structure matters. Proxy materials describe annual meeting voting matters and board oversight, while current reports document board composition changes and common-stock offering documentation connected to an equity distribution arrangement. These filings frame Lipocine’s pipeline development, commercialization agreements, financing tools, risk disclosures and public-company governance.
Lipocine Inc. Chief Executive Officer Mahesh V. Patel purchased 25,000 shares of Lipocine common stock in an open-market transaction at $2.02 per share on April 2, 2026. Following this trade, he directly owns 135,679 shares of Lipocine common stock.
Lipocine Inc. reported topline Phase 3 results for LPCN 1154, an oral brexanolone, in postpartum depression. The study did not meet its primary endpoint, as LPCN 1154 failed to show a statistically significant improvement in HAM-D total score versus placebo at hour 60 in the full analysis set.
Despite missing the primary endpoint, LPCN 1154 was well tolerated, with a favorable safety profile supporting outpatient use and no treatment-related serious adverse events, excessive sedation, loss of consciousness, or treatment-related discontinuations. A post hoc analysis of patients with a history of psychiatric conditions showed signals that may inform a potential development path. Based on these data, Lipocine has applied for breakthrough therapy and fast track designations and plans to preserve capital while engaging stakeholders to evaluate options, which may include further LPCN 1154 work, other pipeline programs, or strategic transactions.
Lipocine Inc. reported full-year 2025 results with revenue of $2.0 million and a net loss of $9.6 million, compared with revenue of $11.2 million and net income of $8,352 in 2024. The revenue decline mainly reflects lower license revenue, partly offset by higher TLANDO royalty revenue.
Research and development expenses rose to $8.6 million from $7.4 million as the company increased clinical and personnel spending, while general and administrative expenses declined to $3.8 million from $5.0 million due to lower professional, legal, tax and insurance costs. As of December 31, 2025, Lipocine held $14.9 million in unrestricted cash, cash equivalents and marketable investment securities, which increased to approximately $24.7 million as of March 6, 2026, primarily from an at-the-market stock offering.
The company highlighted progress in its pipeline, including candidates for postpartum depression, major depressive disorder, epilepsy, essential tremor, obesity management, liver cirrhosis symptoms and preterm birth prevention, alongside TLANDO, an FDA-approved oral testosterone product.
Lipocine Inc. is a clinical-stage biopharmaceutical company using a proprietary oral lipid-based delivery platform to improve absorption of hard‑to‑deliver drugs, with a focus on CNS disorders, liver disease, and hormone therapies.
The company has transformed its testosterone replacement therapy franchise into a licensing model. Verity holds exclusive rights to TLANDO in the U.S. and Canada, paying Lipocine $2.5 million on signing, $5 million in February 2024, $2.5 million in December 2024 and $1 million in January 2026, plus up to $259 million in potential milestones and tiered royalties of 12%–18%. Additional TLANDO licenses cover South Korea (SPC), Gulf Cooperation Council countries (Pharmalink) and Brazil (Aché), each with upfront fees, milestones and supply arrangements.
Lipocine’s lead CNS asset, LPCN 1154 for postpartum depression, has completed enrollment and last patient visit in a Phase 3 trial, with data expected in April 2026 to support a planned 505(b)(2) NDA. Other neuroactive steroid programs target major depressive disorder, epilepsy and essential tremor. In liver disease, LPCN 1148 showed Phase 2 proof‑of‑concept in decompensated cirrhosis with improved muscle mass and fewer decompensation events. Research and development spending was $8.6 million in 2025 versus $7.4 million in 2024. As of March 9, 2026, Lipocine had 7,299,687 common shares outstanding and reported a $16.4 million aggregate market value of non‑affiliate holdings as of June 30, 2025.
Lipocine Inc. has activated a stock sales program that lets it issue and sell up to $50,000,000 of common stock through A.G.P./Alliance Global Partners as its sales agent. These shares may be sold from time to time into the market under an existing equity distribution agreement first signed in April 2024.
The company also provided a legal opinion from Dorsey & Whitney LLP confirming the validity of the shares to be issued under this arrangement.
LivePerson, Inc. is offering up to $50,000,000 of common stock pursuant to a sales agreement with A.G.P./Alliance Global Partners.
The supplement increases the prior aggregate program (previously $10,616,169) to $50,000,000, which includes 1,603,431 shares previously sold for an aggregate purchase price of $10,615,576. The supplement states there remains $39,384,424 available for sale from and after the date of this prospectus supplement dated February 26, 2026.
Lipocine Inc. filed a current report to make available an updated corporate presentation used in meetings with investors, analysts and other stakeholders. The updated presentation is included as Exhibit 99.1 to the report. Lipocine’s common stock, par value $0.0001 per share, trades on The NASDAQ Stock Market LLC under the symbol LPCN.
Lipocine Inc. reported preliminary cash and cash equivalents of approximately $19 million as of January 31, 2026, based on unaudited internal estimates. The company also announced that the last patient has completed the final study visit in its pivotal Phase 3 trial of LPCN 1154, an oral brexanolone candidate for treating postpartum depression.
The randomized, double-blind, placebo-controlled study enrolled 90 women with severe postpartum depression, with an average baseline HAM-D score of 28.3. LPCN 1154 showed a favorable safety profile, with only mild to moderate nervous system adverse events and no drug discontinuations, excessive sedation, loss of consciousness, or drug-related serious adverse events.
The single confirmatory outpatient Phase 3 trial is expected to support a planned 505(b)(2) NDA submission in 2026. Lipocine highlights LPCN 1154’s short 48-hour oral treatment regimen and at-home administration as potential advantages over existing postpartum depression therapies.
Squadron Master Fund LP and affiliated parties reported a significant passive stake in Lipocine Inc. common stock. They beneficially own 530,000 shares of Lipocine’s common stock, representing 9.5% of the class, based on 5,551,931 shares outstanding as of November 5, 2025.
Squadron Capital Management, LLC, as investment adviser to private funds including Squadron Master Fund LP, and its partners Matthew Sesterhenn and William Blank may be deemed beneficial owners of these shares, with shared voting and dispositive power over 530,000 shares and no sole power. They expressly disclaim beneficial ownership of the securities, and state the position is held in the ordinary course of business and not to change or influence control of Lipocine.